"Budesonide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.
| Descriptor ID |
D019819
|
| MeSH Number(s) |
D04.210.500.745.745.654.105
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Budesonide".
Below are MeSH descriptors whose meaning is more specific than "Budesonide".
This graph shows the total number of publications written about "Budesonide" by people in this website by year, and whether "Budesonide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 1 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Budesonide" by people in Profiles.
-
Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1; 12(1):9-14.
-
Zangrilli J, Mansfield LE, Uryniak T, O'Brien CD. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2011 Sep; 107(3):258-65.e2.
-
Oshodi A, Dysart K, Cook A, Rodriguez E, Zhu Y, Shaffer TH, Miller TL. Airway injury resulting from repeated endotracheal intubation: Possible prevention strategies. Pediatr Crit Care Med. 2011 Jan; 12(1):e34-9.
-
Loza MJ, Foster S, Peters SP, Penn RB. Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. J Allergy Clin Immunol. 2008 Mar; 121(3):750.e1-5.e3.
-
Gawchik SM. Successful treatment of previously uncontrolled adult asthma with budesonide inhalation suspension: five-year case histories. Ann Pharmacother. 2007 Oct; 41(10):1728-33.
-
Tliba O, Cidlowski JA, Amrani Y. CD38 expression is insensitive to steroid action in cells treated with tumor necrosis factor-alpha and interferon-gamma by a mechanism involving the up-regulation of the glucocorticoid receptor beta isoform. Mol Pharmacol. 2006 Feb; 69(2):588-96.
-
Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. J Clin Pharmacol. 2004 Jan; 44(1):67-72.
-
Leflein JG, Gawchik SM, Galant SP, Lyzell E, Young M, Cruz-Rivera M, Walton-Bowen K, Smith JA, Fitzpatrick S. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc. 2001 Nov-Dec; 22(6):359-66.